rapamycin-resistant T-cell therapy · cell therapy
RAPA-201
1 active trials, targeting T cells. Not approved for any biomarker on marked.bio yet.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| ALK fusion | 1 | 1 | Phase 1/2 |
Sponsors
Industry sponsors leading active biomarker-selected trials of RAPA-201.
- Rapa Therapeutics 1
Trials
1 of 1 trials shown
-
RAPA-201 Therapy of Solid Tumors
…c alterations and mutations (including but not limited to BRAF, BRCA, EGFR mutations, and ALK translocations) must have either received targeted therapy for such conditions or provided written docum…
ALK fusionSolid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
No trials match these filters.